

Speakers



Sigrid Guhr
AbbVie, Germany



Sue Mann
Sue Mann Consultancy, U.K.



Elfriede Maus
AbbVie, Germany



Jef van Schuerbeek
Consulting bvba, Belgium

GMP meets Development

GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing



Live Online Training from 16–18 November 2021



Highlights

- Legal Requirements and Authority Inspections
 - EU and FDA - what is really required
 - ICH Q8
 - Data Integrity
 - Pre-approval Inspections
 - GMP/GDP/GCP Interface
- GMP Issues and Best Practices
 - GMP from Phase 1 to Phase 3
 - Qualification and Validation
 - Analytical Development
 - IMP Manufacturing, Packaging and Supply
 - Change Control
 - The Role of the QP
- Case Studies and Practical Examples
 - PSF and CTD
 - Cleaning Validation
 - Deviations
 - Stability Studies
 - Data Integrity

With a View on the Detailed Commission guideline on GMP for IMPs (applies as of 31 January 2022)!

Objective

During this Live Online Training Course, specialists will share their expert knowledge about all important GMP aspects in Pharmaceutical Development and Investigational Medicinal Product (IMP) Manufacturing. You will be able to elaborate and discuss both EU and FDA requirements.

Background

Not only in the manufacturing of marketed products (c)GMP Compliance is mandatory. Also in the manufacturing of IMP supplies, compliance with the applicable GMP Guidelines is obligatory. But which GMP requirements are the applicable ones? And do the requirements differ from clinical phase 1 to phase 3? And what is the role of ICH Q8, Q9, Q10 and Q12?

With the third revision of ICH E6 (ICH E6(R3)), the GMP for IMP principles will be expanded to the following: Risk-based approaches should be considered when implementing proportionate measures to ensure GMP and the appropriate shipping and handling of the IMP.

Previously, the WHO already published two new draft documents relating to Development and GMP for IMPs: „Good Practices for Research and Development Facilities“ and „GMP for IMPs“.

In addition, instead of the current EU GMP Annex 13 (Manufacture of IMPs), the Detailed Commission guidelines on GMP for IMPs for human use will apply as of 31 January 2022.

Complex challenges have to be faced and resolved to guarantee high quality products. The safety of the drug and hence also the patient should always be the main focus. Terminated studies or studies without reliable results will lead to extensive extra costs and delays in the whole development and approval process.

This Live Online Training has been designed by the ECA to broaden your knowledge and to consolidate the various GMP aspects which need to be considered in a successful development of a new pharmaceutical product.

Target Audience

This Live Online Training Course has been designed for R&D personnel involved in Pharmaceutical Development, IMP Manufacturing, Quality Control, Quality Assurance, and Regulatory Affairs.

Programme

Provisional timetable, the actual schedule may vary depending on the situation.

Day 1

09.00 - 09.15 h Welcome/Introduction

09.15 - 10.15 h Global GMP Requirements from Phase 1 to Scale-up and Transfer

- Global requirements: applicable law, directives, guides and guidelines: what is really required
- A comparison of FDA and European requirements and expectations

10.15 - 10.30 h Break

10.30 - 11.30 h IMPs in the Context of ICH Q8, Q9, Q10 and Q12

- How to integrate Quality by Design
- Risk Analysis in pharmaceutical development
- Life cycle concept

11.30 - 12.00 h The GMP/GDP/GCP Interface

- Reconstitution
- Pre-requisites for randomisation and blinding
- Distribution
- Site-to-site transfers
- Shelf life extension
- The QP: where does the responsibility end?

12.00 - 12.30 h Q&A Session 1

12.30 - 13.30 h Break

13.30 - 14.15 h IMP Manufacturing: How much Qualification and Validation is needed?

- Qualification vs. Validation
- What can be found in the regulations
- DQ/IQ/OQ of equipment
- Cleaning validation vs. cleaning verification
- How much process validation is needed?

14.15 - 14.45 h Cleaning Validation / Verification in Pharmaceutical Development

14.45 - 15.00 h Break

15.00 - 15.45 h Change Control for IMPs

- What is required
- What is important
- What are the benefits
- How to implement



15.45 - 16.45 h

Case study / Interactive session 1
Transition of GMP Requirements from Phase 1 to Phase 3 and the Interface to Development Work

- Challenges and Differences
- How to apply phase appropriate GMPs
- Managing a GMP Lifecycle

16.45 - 17.15 h Q&A Session 2

Day 2

09.00 - 10.15 h Analytical Development (ICH Q14)

- From method development to method validation
- How to deal with genotoxic and other impurities
- Quality control and IMP release
- Analytical Qualification

10.15 - 10.30 h Break

10.30 - 11.30 h The Role of the QP in Pharmaceutical Development and IMP Release

- Responsibilities
- Co-operation with Head of Production and Head of Quality Control
- Confirmation of Compliance, certification and batch release
- Comparators
- Complaints and recalls

11.30 - 12.00 h Q&A Session 3

12.00 - 13.00 h Break

13.00 - 14.00 h How to handle Deviations in an R&D Environment

14.00 - 14.15 h Break



14.15 - 15.15 h Case study / Interactive session 2 Stability Studies throughout the Development of a new Product

- Different types of products in CT studies (and support)
- APIs and various dosage forms
- Late stage stability strategies

15.15 - 15.30 Coffee Break

15.30 - 16.30 h The FDA Pre-Approval Inspection (PAI)

- Involvement of the R&D Department
- What the FDA will look for
- What happens at FDA during and after the PAI
- Responding to FDA after the PAI

16.30 - 17.00 h Q&A Session 4

Day 3

09.00 - 09.45 h Important Documents in Pharmaceutical Development

- Early documentation
- CTD
- PSF: style and content
- Case studies



09.45 - 10.45 h Case study / Interactive session 3 Data Integrity

- Manufacturer's understanding of data integrity, needs and benefit
- Regulatory expectations
- Hybrid systems (paper and electronic records) - how to ensure data integrity?

10.45 - 11.00 Coffee Break

11.00 - 12.15 h Packaging and Supply of Clinical Trial Materials

- GMP requirements
- Quality control of packaging and labelling
- Handling and sourcing of comparators
- Randomisation and blinding

12.15 - 13.00 h Q&A Session 5

Speakers



Sigrid Guhr, AbbVie Deutschland GmbH, Germany (form. Abbott)

Sigrid Guhr is a mathematician and leads GMP QA Qualification & Validation (EU) for equipment, facilities, utilities and computerized systems. She has more than 30 years of experience in the pharmaceutical industry, started as programmer, worked as a validation consultant, then as validation manager for computerized systems used by pharmacovigilance. Her present responsibilities include validation, qualification, and compilation of quality management systems for the software life cycle, vendor audits, risk analyses, and concepts for data integrity assurance.



Sue Mann
Sue Mann Consultancy, U.K.

Sue Mann has more than 30 years experience in the Pharmaceutical Industry, mainly in Quality Assurance, Clinical Trials supply and production support. In her last position, Sue was Vice President of International Quality Assurance at Shire Pharmaceuticals.



Elfriede Maus, AbbVie Deutschland GmbH, Germany (form. Abbott)

Elfriede Maus leads Regulatory Compliance and Inspection Management at AbbVie Deutschland GmbH & Co.KG in Ludwigshafen. Working in Pharmaceutical Industry for more than 30 years she gained broad knowledge of regulations in various GxP areas. In different roles within QA for marketed products and R&D QA, she was/is responsible for managing regulatory inspections carried out by regulators from all over the world. She is a certified Auditor for Quality Management.



Jef van Schuerbeek
Consulting bvba, Belgium

Jef van Schuerbeek spent more than 20 years in pharmaceutical R&D, among others at Lilly Clinical Operations in Belgium, before he became a freelance consultant.

Reservation Form (Please complete in full)



Live Online Training: GMP meets Development
16-18 November 2021

If the bill-to-address deviates from the specifications on the right, please fill out here:

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg
GERMANY

Title, first name, surname

Department

Company

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

Country

Phone / Fax

ZIP Code

E-Mail (Please fill in)

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
 2. If you have to cancel entirely we must charge the following processing fees:
 - Cancellation until 2 weeks prior to the conference 10 %
 - Cancellation until 1 week prior to the conference 50 %
 - Cancellation within 1 week prior to the conference 100 %
- CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of can-

cellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed!) (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.



Date of the Live Online Training

Tuesday, 16 November 2021, 09.00 – 17.15 h
Wednesday, 17 November 2021, 09.00 – 17.00 h
Thursday, 18 November 2021, 09.00 – 13.00 h

All times mentioned are CET.

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At <http://www.webex.com/test-meeting.html> you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate, plus VAT)

ECA Members € 1,990
APIC Members € 2,090
Non-ECA Members € 2,190
EU GMP Inspectorates € 1,095

The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this Live Online Training.
CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg, Germany
Phone +49(0)62 21/84 44-0 | Fax +49(0)62 21/84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content please contact:

Dr Andrea Kühn-Hebecker (Operations Director) at
+49(0)62 21/84 44 35, or at
kuehn@concept-heidelberg.de.

For questions regarding organisation please contact:

Ms Marion Grimm (Organisation Manager) at
+49(0)62 21/84 44 18, or per e-mail at
grimm@concept-heidelberg.de.

Your Benefit

Internationally Acknowledged Certificate from ECA Academy

The EU GMP Guide requires: „... All personnel should be aware of the principles of Good Manufacturing Practice that affect them and receive initial and continuing training...“. This is why you receive an acknowledged participant certificate, which lists the contents of the seminar in detail and with which you document your training.